Donors | IPAH patients | |
Lung samples | 15 | 16 |
Age years | 41.7±13.2 | 34.1±10.6 |
Male/female | 10/5 | 5/11 |
Height cm | 175±9 | 170±8 |
Weight kg | 73.6±9.9 | 61.2±13.3* |
mPAP mmHg | 71.2±16.6 | |
PVR dyn·sec·cm−5 | 1845±669 | |
6MWD m | 280±187 | |
NYHA class | III–IV | |
NT-proBNP pg·mL−1 | 4412±2445 | |
CRP mg·dL−1 | 1.2±2.4 | |
PAH targeted therapy | ||
ERA | 1 | |
ERA+PDE5i | 1 | |
sGCs+PGI | 1 | |
PDE5i+PGI | 4 | |
ERA+PDE5i+PGI | 7 | |
PDE5i+PGI+CCB | 1 | |
Unknown | 1 |
Data are presented as n or mean±sd. mPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; 6MWD: 6-min walking distance; NYHA: New York Heart Association; NT-proBNP: N-terminal pro-brain natriuretic peptide; CRP: C-reactive protein; ERA: endothelin receptor antagonists; PDE5i: phosphodiesterase type 5 inhibitor; sGCs: soluble guanylate cyclase stimulator; PGI: prostacyclin analogue; CCB: calcium channel blocker. *: p≤0.05.